The objective of this retrospective study is to assess the effectiveness and safety of two beta-emitting prostate-specific membrane antigen (PSMA) radioligands, [177Lu]Lu and [161Tb]Tb, in heavily treated patients with metastatic castration-resistant prostate cancer (mCRPC). A total of 148 cycles of beta-emitting PSMA radioligand therapy were given to 53 patients at a specialized cancer care center in Amman, Jordan. This treatment was offered following the exhaustion of all prior treatment modalities. Approximately half of the cases (n = 26) demonstrated an initial partial response to PSMA radioligand therapy. Moreover, roughly one-fourth of the patients (n = 13) exhibited a sustained satisfactory biochemical response, which qualified them to receive a total of six PSMA radioligand therapy cycles and maintain continued follow-up for additional treatment cycles. This was reflected by an adequate prostate-specific antigen (PSA) decline and a concomitant partial response evident on [68Ga]Ga-PSMA positron emission tomography/computed tomography imaging. A minority of patients (n= 18; 34%) experienced side effects. Generally, these were low-grade and self-limiting toxicities. This study endorses previous research evidence about PSMA radioligand therapy's safety and efficacy. It also provides the first clinical insight from patients of Arab ethnicity. This should facilitate and promote further evidence, both regionally and internationally.
Cancers. 2024 May 23*** epublish ***
Akram Al-Ibraheem, Ahmed Saad Abdlkadir, Deya' Aldeen Sweedat, Stephan Maus, Ula Al-Rasheed, Samer Salah, Fadi Khriesh, Diyaa Juaidi, Dina Abu Dayek, Feras Istatieh, Farah Anwar, Aisha Asrawi, Alaa Abufara, Mohammad Al-Rwashdeh, Ramiz Abu-Hijlih, Baha' Sharaf, Rami Ghanem, Hikmat Abdel-Razeq, Asem Mansour
Department of Nuclear Medicine, King Hussein Cancer Center (KHCC), Al-Jubeiha, Amman 11941, Jordan., Department of Nuclear Medicine, Saarland University Medical Center, D-66421 Homburg, Germany., Department of Medicine, King Hussein Cancer Center (KHCC), Amman 11941, Jordan., Department of Nuclear Medicine, Klinikum Fulda, Pacelliallee 4, 36039 Fulda, Germany., Department of Nuclear Medicine, Warith International Cancer Institute, Karbala 56001, Iraq., Department of Nursing, King Hussein Cancer Center (KHCC), Amman 11941, Jordan., Department of Radiation Oncology, King Hussein Cancer Center (KHCC), Amman 11941, Jordan., Department of Surgery, King Hussein Cancer Center (KHCC), Amman 11941, Jordan., Department of Diagnostic Radiology, King Hussein Cancer Center (KHCC), Amman 11941, Jordan.